PH10.{5,11-12} | PH10.{5,11-12} | Legal, Ethical and Regulatory Frameworks for Drug Use — SDL Guide — Summary & Reflection

KEY TAKEAWAYS

India's drug regulatory framework is built on the Drugs and Cosmetics Act 1940, the NDPS Act 1985, and the New Drugs and Clinical Trials Rules 2019, administered by CDSCO. Schedules H, H1, and X define progressively stricter prescription requirements; Schedule X drugs (including benzodiazepines and opioids) require prescriptions in duplicate with quantity in words. Off-label prescribing is legally permitted but requires informed consent documentation and clinical evidence. Prescribing for self or close family is strongly discouraged on ethical grounds. Drug development follows a systematic pipeline: pre-clinical testing, then Phase I (safety/PK, healthy volunteers), Phase II (efficacy signal, patients), Phase III (confirmatory RCT, market authorisation basis), and Phase IV (post-marketing surveillance). Good Clinical Practice (ICH E6(R2)) and the Declaration of Helsinki govern research ethics; in India, ICMR guidelines and IEC approval are mandatory. Pharmacovigilance reporting of suspected ADRs is a professional obligation.

REFLECT

Consider the ethical tension between research advancing new medicines and protecting individual research participants. The drugs that will save lives in the next decade require clinical trials being conducted today. How do you balance your obligation to future patients (who need better drugs) with your obligation to current patients (who must not be harmed by research)? Consider also: India's large, genetically diverse, and often treatment-naive patient population makes it an attractive research site for global pharmaceutical companies. What additional ethical safeguards does this create — and are they adequately implemented in the institution where you train?